It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Particle therapy (PT) used for cancer treatment can spare healthy tissue and reduce treatment toxicity. However, full exploitation of the dosimetric advantages of PT is not yet possible due to range uncertainties, warranting development of range-monitoring techniques. This study proposes a novel range-monitoring technique introducing the yet unexplored concept of simultaneous detection and imaging of fast neutrons and prompt-gamma rays produced in beam-tissue interactions. A quasi-monolithic organic detector array is proposed, and its feasibility for detecting range shifts in the context of proton therapy is explored through Monte Carlo simulations of realistic patient models and detector resolution effects. The results indicate that range shifts of
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Western Norway University of Applied Sciences, Department of Computer Science, Electrical Engineering and Mathematical Sciences, Bergen, Norway (GRID:grid.477239.c) (ISNI:0000 0004 1754 9964)
2 Haukeland University Hospital, Department of Oncology and Medical Physics, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393); University of Bergen, Department of Physics and Technology, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443)
3 Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, OncoRay–National Center for Radiation Research in Oncology, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); Institute of Radiooncology–OncoRay, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany (GRID:grid.40602.30) (ISNI:0000 0001 2158 0612)
4 Delft Universiy of Technology, Delft, The Netherlands (GRID:grid.5292.c) (ISNI:0000 0001 2097 4740)
5 The University of Manchester, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
6 North Carolina State University, Department of Nuclear Engineering, Raleigh, USA (GRID:grid.40803.3f) (ISNI:0000 0001 2173 6074)
7 Ruder Boskovic Institute, Zagreb, Croatia (GRID:grid.4905.8) (ISNI:0000 0004 0635 7705)
8 Target Systemelektronik GmbH & Co. KG, Wuppertal, Germany (GRID:grid.4905.8)
9 Haukeland University Hospital, Department of Oncology and Medical Physics, Bergen, Norway (GRID:grid.412008.f) (ISNI:0000 0000 9753 1393)
10 Holland Particle Therapy Centre, Delft, The Netherlands (GRID:grid.477239.c)
11 KU Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884)
12 University of Bergen, Department of Physics and Technology, Bergen, Norway (GRID:grid.7914.b) (ISNI:0000 0004 1936 7443)